Vaxcyte, Inc. Reports Quarterly Results for Quarter Ended June 30, 2026

What Happened

• On August 5, 2026, Vaxcyte, Inc. (PCVX) announced its financial results for the quarter ended June 30, 2026 via a press release. The press release text is furnished with the Form 8‑K as Exhibit 99.1 and is incorporated by reference into the filing.

Key Details

• Filing date: August 5, 2026. Quarter covered: quarter ended June 30, 2026.
• The press release reporting the quarterly results is attached as Exhibit 99.1 to the Form 8‑K.
• The company states that the furnished exhibit is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except by specific reference.

Why It Matters

• This 8‑K signals Vaxcyte has updated the market with its latest quarterly earnings and financial condition; investors should review the Exhibit 99.1 press release for revenue, profitability, cash position, and any management commentary or guidance.
• The 9.01 disclosure clarifies legal treatment of the furnished press release (limited Section 18 liability and limited incorporation), which affects how the information may be used in other SEC filings.